Immuno-oncology combinations: raising the tail of the survival curve.

Cancer Biol Med · 2016 · PMC4944548 · PMID 27458526

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

very close to significanceP =0.051so close (0.05 < p ≤ 0.1)

In a phase 3 study with intraregional injection of T-VEC compared to GM-CSF alone, there was an increase in median OS from 18.9 to 23.3 months with a P -value very close to significance ( P =0.051).

also in 191 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.